HeartBeam Inc. has enrolled the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The enrollment, conducted by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, represents a pivotal milestone in generating clinical data needed to broaden the technology's medical applications.
The importance of this development lies in the potential to transform cardiac emergency response. Currently, heart attack detection typically requires hospital-based equipment and professional interpretation. HeartBeam's technology aims to create the first cable-free device capable of collecting electrocardiogram signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG. This portable platform could enable detection wherever patients are located, potentially reducing critical time delays in diagnosis and treatment.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software receiving clearance in December 2025. The specific cleared indications for use are detailed on the company's website at https://www.heartbeam.com/indications. The ALIGN-ACS study represents the next logical expansion of this platform technology toward acute coronary syndrome detection.
For patients, the implications are significant. Early and accurate heart attack detection outside medical facilities could direct patients to appropriate care more rapidly, potentially improving outcomes. For healthcare systems, portable detection technology could reduce unnecessary emergency department visits while ensuring those experiencing actual cardiac events receive timely intervention. The technology's design for use outside medical facilities aligns with broader trends toward decentralized healthcare and remote patient monitoring.
HeartBeam holds over 20 issued patents related to its technology enablement, protecting its innovative approach to cardiac monitoring. The company's progress can be tracked through its newsroom at https://ibn.fm/BEAT, where updates regarding the NASDAQ-listed company are available. The ALIGN-ACS pilot study represents a crucial step toward validating the system's effectiveness for heart attack detection, potentially expanding the technology's impact beyond its current arrhythmia assessment capabilities.
The medical technology sector continues to evolve toward more accessible diagnostic tools, and HeartBeam's progress in this pilot study contributes to that transformation. Successful clinical data from the ALIGN-ACS study could position the HeartBeam System as a comprehensive cardiac assessment tool, addressing both rhythm abnormalities and acute coronary events through the same portable platform. This development matters because it addresses a critical gap in cardiac care: the ability to accurately detect heart attacks outside clinical settings, potentially saving lives through earlier intervention.
